SEC Comment Letter for Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251) (CTXR) — Feb 29, 2024
Citius Pharmaceuticals, Inc. (CTXR) (CIK 0001506251)
Date: Feb. 29, 2024 · CIK: 0001506251 · Accession: 0000000000-24-002273
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-277319
Letter
United States securities and exchange commission logo February 29, 2024 Leonard Mazur Chief Executive Officer Citius Pharmaceuticals, Inc. 11 Commerce Drive, First Floor Cranford, NJ 07016 Re:Citius Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed February 23, 2024 File No. 333-277319 Dear Leonard Mazur: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Lorna A. Knick, Esq.
Show Raw Text
United States securities and exchange commission logo
February 29, 2024
Leonard Mazur
Chief Executive Officer
Citius Pharmaceuticals, Inc.
11 Commerce Drive, First Floor
Cranford, NJ 07016
Re:Citius Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed February 23, 2024
File No. 333-277319
Dear Leonard Mazur:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Lorna A. Knick, Esq.